[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369172-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369172-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-impact-of-advanced-medical-therapies-on-time-to-resection-and-colorectal-cancer-outcomes-in-ulcerative-colitis-patients-undergoing-colectomy","The impact of advanced medical therapies on time to resection and colorectal cancer outcomes in ulcerative colitis patients undergoing colectomy","","Background: Advanced medical therapies may influence timing of colectomy and oncological outcomes in ulcerative colitis (UC). Methods: This cohort study included UC patients who underwent colectomy from 2003 to 2022 at two referral centers in Belgium and the Netherlands. Exposure was advanced medical therapy use; primary outcomes were time to colectomy and colorectal cancer (CRC) rate across four eras. Results: Among 716 patients, advanced therapy use rose markedly, while median time to colectomy and overall CRC diagnosis rates remained stable. CRC was less frequent with advanced therapies but incident cancers were higher, linked to worse CRC-related survival. Conclusion: Despite increased advanced therapy adoption, colectomy timing and CRC rates were unchanged over two decades, while incidental cancer risk increased and CRC survival decreased in advanced-therapy patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-impact-of-advanced-medical-therapies-on-time-to-resection-and-colorectal-cancer-outcomes-in-ulcerative-colitis-patients-undergoing-colectomy/369172/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-impact-of-advanced-medical-therapies-on-time-to-resection-and-colorectal-cancer-outcomes-in-ulcerative-colitis-patients-undergoing-colectomy/369172.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How did advanced medical therapy use change over time in the cohort?","Question",{"text":63,"@type":64},"Use of advanced therapies increased substantially from 36.8% in P1 (2003-2007) to 89.7% in P4 (2018-2022).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Did advanced therapies shorten the time to colectomy?",{"text":68,"@type":64},"Median time to colectomy was comparable across periods, with no significant change over time (P1 vs P4 not significant).",{"name":70,"@type":61,"acceptedAnswer":71},"What was the relationship between advanced therapies and colorectal cancer outcomes?",{"text":72,"@type":64},"CRC proportion was lower in patients treated with advanced therapies, but incident cancer rates were higher and CRC-related survival was reduced in the advanced-therapy group.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369172,1790357762,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","The impact of advanced medical therapies on time toresection and colorectal cancer outcomes in ulcerative colitis patients undergoing colectomy  \nEva Visser1,, Antonio Luberto2, Lianne Heuthorst1, Roel Hompes1, SéverineVermeire3,, Geert R. D’Haens4,, Willem A. Bemelman1, André D’Hoore2, Gabriele Bislenghi2,*,†,, Christianne J. Buskens1,†,  \n1Department of Surgery, Amsterdam University Medical Centre, location VUMC, Amsterdam, The Netherland 2Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium  \n3Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium  \n4Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Amsterdam, The Netherlands  \n*Corresponding author: Gabriele Bislenghi, Department of Abdominal Surgery, University Hospitals Leuven, Belgium ([gabriele.bislenghi@uzleuven.be](gabriele.bislenghi@uzleuven.be)) .†Gabriele Bislenghi and Christianne J. Buskens share senior authorship and appear in alphabetic order.  \nAbstract  \nBackground: We aimed to evaluate the impact of advanced medical therapies (biologicals and small molecules) on time to colectomy and oncological outcomes in ulcerative colitis (UC) .  \nMethods: This cohort study included UC patients who underwent colectomy between 2003 and 2022 at 2 referral centers in Belgium and the Netherlands. Exposure was the use of advanced medical therapies. Primary outcomes were time to colectomy and colorectal cancer (CRC) rate, compared between 4 periods: P1 (2003-2007), P2 (2008-2012), P3 (2013-2017), and P4 (2018-2022) . Secondary outcomes were oncological outcomes, including incidental cancers found unexpectedly in resection specimens or during endoscopic follow-up for medication switch. Results: Among 716 patients, the usage of advanced therapies increased from 36.8% in P1 to 89.7% in P4 ( P \u003C .0001) . Median time to colectomy remained comparable (P1: 7.1 years [interquartile ranges (IQR), 2.8-12.9] vs P4: 7.2 years [IQR, 2.7-14.6]; P = not significant) . Colectomy and colorectal cancer was diagnosed in 72 (10 . 1%) patients, with no significant change over time ( P = .44) . Proportion of CRC was lower in patients treated with advanced therapies (4 .7% vs 23.6%, P \u003C .0001) and related to a shorter follow-up (median 6.1 vs 10.3 years, P \u003C .0001) . Advanced therapy patients had higher incidental cancer rates (37. 5% vs 8.3%, P = .002), which was associated with reduced CRC-related survival (HR for CRC-related death: 3.3, 95% CI 1.17-9.4; P = .02) .  \nConclusion: Despite increased usage of advanced medical therapies, time to resection and CRC rates have remained unchanged in UC patients undergoing colectomy over the past 2 decades. Advanced therapy patients had higher incidental cancers rates, associated with decreased CRC survival. Awareness of timely colectomy is crucial for this group.  \nKey words: ulcerative colitis; colorectal cancer; colectomy; surgery.  \n1. Introduction  \nPatients with ulcerative colitis (UC) face an elevated risk of developing colorectal cancer (CRC) due to chronic inflammation that leads to neoplastic progression.1–7 Risk factors for CRC in UC patients include male sex, family history of CRC, concomitant primary sclerosing cholangitis (PSC), and longstanding, extensive, and severe colitis. Therefore, the European Crohn’s and Colitis Organisation (ECCO) recommends performing surveillance colonoscopy in patients with at least distal colitis 8 years after symptom onset to detect neoplasia early.8  \nSince the introduction of the first tumor necrosis factor-α inhibitor (anti-TNF-α) in 1998, the medical landscape has evolved, with now more than 5 distinct mechanisms of action available by 2022, including anti-TNFs (infliximab, adalimumab, and golimumab), the integrin receptor antagonist vedolizumab, interleukin 12/23 inhibitors (ustekinumab,  \nmirikizumab), Janus kinase (JAK) inhibitors (tofacitinib, filgotinib, and upadacitinib), and S1P receptor modulators (ozanimod","cbCaibLgyNtnPfgU","https://ap.wps.com/l/cbCaibLgyNtnPfgU","pdf",513249,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## CRC risk in ulcerative colitis\n## Evolution of therapies and potential impacts\n## Need to link therapy use with clinical data","[{\"question\":\"How did advanced medical therapy use change over time in the cohort?\",\"answer\":\"Use of advanced therapies increased substantially from 36.8% in P1 (2003-2007) to 89.7% in P4 (2018-2022).\"},{\"question\":\"Did advanced therapies shorten the time to colectomy?\",\"answer\":\"Median time to colectomy was comparable across periods, with no significant change over time (P1 vs P4 not significant).\"},{\"question\":\"What was the relationship between advanced therapies and colorectal cancer outcomes?\",\"answer\":\"CRC proportion was lower in patients treated with advanced therapies, but incident cancer rates were higher and CRC-related survival was reduced in the advanced-therapy group.\"}]","The impact of advanced medical therapies on time to resection and colorectal cancer outcomes in ulcerative colitis patients undergoing colectomy | PDF",1790181168,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a0b8776f4543f72f90171116fff04bd.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc202ea95449c00895700a27540c22f4.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a3f1304c099527cfdaf3731d231379c.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32bb2d28c6072b6933b5430231c068c1.webp",980,1287]